Type 2 Diabetes

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

Adults who eat greater amounts of meat may have increased risk for developing type 2 diabetes, according to data published in The Lancet Diabetes & Endocrinology.

Exposure to high amounts of certain per- and polyfluoroalkyl substances during pregnancy may cause long-term increases in weight and fat mass, according to research published in The Journal of Clinical Endocrinology & Metabolism.

Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.

The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced.

Canagliflozin may reduce albuminuria and patient-specific eGFR decline in patients with type 2 diabetes and microalbuminuria, researchers found in a parallel, open-labeled trial.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

The FDA has cleared an automated insulin delivery system for adults aged 18 years and older with type 2 diabetes, Insulet Corp. announced.